These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38544885)

  • 1. Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan.
    Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Ishizuchi K; Tokuyasu D; Handa H; Yasuda M; Kawaguchi N; Kimura T; Suzuki Y; Sugimoto T; Minami N; Takahashi MP; Murai H; Utsugisawa K
    Neurol Clin Pract; 2024 Jun; 14(3):e200276. PubMed ID: 38544885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
    Katyal N; Halldorsdottir K; Govindarajan R; Shieh P; Muley S; Reyes P; Leung KK; Mullen J; Milani-Nejad S; Korb M; Goyal NA; Mozaffar T; Goyal N; Habib AA; Muppidi S
    Muscle Nerve; 2023 Nov; 68(5):762-766. PubMed ID: 37695277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
    Howard JF; Bril V; Vu T; Karam C; Peric S; De Bleecker JL; Murai H; Meisel A; Beydoun SR; Pasnoor M; Guglietta A; Van Hoorick B; Steeland S; T'joen C; Utsugisawa K; Verschuuren J; Mantegazza R;
    Front Neurol; 2023; 14():1284444. PubMed ID: 38318236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
    Singer M; Khella S; Bird S; McIntosh P; Paudyal B; Wadhwani A; Quinn C; Karam C
    Muscle Nerve; 2024 Jan; 69(1):87-92. PubMed ID: 37990374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients.
    Wang P; Zhang B; Yin J; Xi J; Tan Y; Gao F; Zeng F; Chang T; Zhou H; Liang H; Zhao Z; Yang H; Zhao C; Huang S
    Front Neurol; 2024; 15():1407418. PubMed ID: 38966082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    Pane C; Di Stefano V; Cuomo N; Sarnataro A; Vinciguerra C; Bevilacqua L; Brighina F; Rini N; Puorro G; Marsili A; Garibaldi M; Fionda L; Saccà F
    J Neurol; 2024 Sep; 271(9):6209-6219. PubMed ID: 39080054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod.
    Sorrenti B; Laurini C; Bosco L; Strano CMM; Scarlato M; Gastaldi M; Filippi M; Previtali SC; Falzone YM
    Eur J Neurol; 2024 Jul; 31(7):e16306. PubMed ID: 38716750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China.
    Luo S; Jiang Q; Zeng W; Wang Q; Zou Z; Yu Y; Hong D; Zeng Q; Tan S; Zhang Z; Zhang Y; Guo X; Chen J; Zhao Z; Huang S; Shi J; Chen Y; Du L; Yan C; Xi J; Song J; Zhao C;
    Ann Clin Transl Neurol; 2024 Aug; 11(8):2212-2221. PubMed ID: 38973109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efgartigimod in refractory autoimmune myasthenia gravis.
    Remijn-Nelissen L; Tannemaat MR; Ruiter AM; Campman YJM; Verschuuren JJGM
    Muscle Nerve; 2024 Sep; 70(3):325-332. PubMed ID: 38899431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.
    Dos Santos JBR; Gomes RM; da Silva MRR
    Expert Rev Clin Immunol; 2022 Sep; 18(9):879-888. PubMed ID: 35892247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series.
    Horiuchi K; Nakamura S; Yamada K; Inoue T; Oiwa K
    Neuromuscul Disord; 2024 Jun; 39():37-41. PubMed ID: 38772072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control.
    Konno S; Uchi T; Kihara H; Sugimoto H
    Biomedicines; 2024 May; 12(6):. PubMed ID: 38927421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series.
    Song J; Wang H; Huan X; Jiang Q; Wu Z; Yan C; Xi J; Zhao C; Feng H; Luo S
    Front Immunol; 2024; 15():1418503. PubMed ID: 39136012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
    Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
    Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
    Saccà F; Barnett C; Vu T; Peric S; Phillips GA; Zhao S; Qi CZ; Gelinas D; Chiroli S; Verschuuren JJGM
    J Neurol; 2023 Apr; 270(4):2096-2105. PubMed ID: 36598575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center.
    Frangiamore R; Rinaldi E; Vanoli F; Andreetta F; Ciusani E; Bonanno S; Maggi L; Gallone A; Colasuonno A; Tramacere I; Cheli M; Pinna A; Mantegazza R; Antozzi C
    Eur J Neurol; 2024 Apr; 31(4):e16189. PubMed ID: 38164996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.